A 21-year-old Stanford grad just raised $11.6M to build a wearable hormone monitor that doesn’t need blood

Clair Health, a San Francisco startup founded by two Stanford graduates, raised $11.6 million in seed funding led by Khosla Ventures for a noninvasive wearable hormone monitor. The wristband uses 10 biosensors and AI to infer hormonal cycles without blood draws, but peer-reviewed clinical validation has not yet been published. The company plans to ship the device in November as a wellness product, with FDA clearance to follow.

TL;DR Clair Health raised $11.6M from Khosla Ventures for a noninvasive wearable hormone monitor. It ships in November but has no peer-reviewed results yet. Clair Health's wristband uses 10 biosensors and AI to infer hormonal cycles without blood draws, but peer-reviewed clinical validation has not yet been published Clair Health raised $11.6M from Khosla Ventures for a noninvasive wearable hormone monitor. It ships in November but has no peer-reviewed results yet. Clair Health, a San Francisco startup founded by two Stanford graduates, has raised $11.6 million in seed funding to build what it calls the first continuous, noninvasive hormone monitor for women. https://techcrunch.com/2026/06/17/two-stanford-grads-raise-11m-to-build-a-noninvasive-wearable-for-hormone-tracking/ Khosla Ventures led the round, with participation from a16z speedrun, Brydge Club, Treehub, Cartan Capital, AGI House, Insiders VC, and 23andMe co-founder Anne Wojcicki. The company plans to ship the wristband in November as a wellness product, with FDA clearance to follow later. Co-founder Jenny Duan, 21, closed the round the same week she graduated from Stanford with a degree in symbolic systems, according to Fortune. She started the company with Abhinav Agarwal after the two met at Stanford in spring 2025. Agarwal previously helped develop a noninvasive continuous glucose monitor at KOS AI. The device uses a stack of 10 biosensors, including biomagnetic sensors that Clair says are not found in any competing consumer wearable, to read physiological signals like skin temperature, heart rate variability, and electrodermal activity. AI models then interpret those signals to infer where a woman is in her hormonal cycle, tracking estrogen, progesterone, LH, and FSH across more than 130 proprietary biomarkers. The company holds provisional patents on the sensor configuration. “ Right now, to measure hormones, you either do a blood test in a lab or you pee on a stick at home, ” Duan told Fortune. “ Any urine test is also not looking at hormones directly, they’re looking at how your body metabolizes them. ” Clair reports 94% accuracy in classifying menstrual cycle phases, but that figure is benchmarked against daily urine samples, the same standard as at-home ovulation strips, not clinical blood analysis. An independent study through the Stanford Gladstone BeeHive programme is underway, and the company says it plans to publish peer-reviewed results, but no such publication exists yet. The distinction matters because inferring hormone levels from surface-level biosignals, rather than measuring them directly, remains an extraordinary claim that has not been independently validated in the scientific literature. The startup also says it has trained AI to analyse voice-based biomarkers and determine cycle phase after a few minutes of conversation. The wearable market is rapidly evolving https://thenextweb.com/news/apple-watch-losing-ground-whoop-oura-screenless-wearables , with competitors adding women’s health features to existing hardware. WHOOP launched women’s hormonal insights in 2025 and added a women’s-specific blood testing panel this spring, while Oura launched a proprietary AI model for women’s health in February 2026. But none of those incumbents were built from the ground up for hormone monitoring. “ Much of wearable technology being developed is bro-tech for tech-bros, ” said Alex Morgan, a partner at Khosla Ventures. WHOOP recently raised $575 million at a $10.1 billion valuation https://thenextweb.com/news/whoop-series-g-575m-valuation-ipo-health-platform and is heading toward an IPO, while Oura has filed confidentially for its own public listing, reflecting how seriously investors are treating health wearables as an asset class. The global femtech market is projected to nearly triple from $39 billion in 2024 to $97 billion by 2030, according to Grand View Research. Femtech has historically struggled to attract proportional venture capital https://thenextweb.com/news/europes-ai-boom-is-leaving-femtech-behind , with global investment peaking at roughly $2 billion in 2021 before collapsing as AI consumed the lion’s share of funding. Clair’s round suggests at least some capital is returning to the category. Early testing identified nine unique sub-phases in the female hormone cycle, according to Tech Funding News, challenging the long-standing four-phase model used in women’s health. Clair already has a 25,000-person waitlist, has sold out its presale, and has received more than 100 letters of intent from fertility clinics. The longer-term roadmap includes perimenopause monitoring, hormone replacement therapy calibration, and diagnostics for conditions like PCOS and endometriosis. Privacy is central to the pitch. The company says all data is processed on the phone rather than in the cloud, using zero-knowledge encryption, a design choice that addresses growing consumer anxiety about health data security. Women were not required to be included in US clinical trials until 1993, a historical gap that Duan has cited as a motivating factor. The pricing has not been independently confirmed outside of reporting by TechCrunch, which cited a price of $369 for the device and a $9.99 monthly subscription. Clair is entering the market as a wellness product, not a medical device, which means it does not need FDA clearance to ship but also cannot make diagnostic claims. The company says it will pursue regulatory approval later. Whether a wristband can reliably infer hormone levels from surface biosignals is the central question Clair will need to answer with published data. The company has the funding, the waitlist, and the investor roster. What it does not yet have is the peer-reviewed evidence that would separate its claims from the marketing of every other health wearable startup that has promised more than it delivered. Get the most important tech news in your inbox each week.